Anifrolumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Anifrolumab
Monoclonal antibody
Type Whole antibody
Source Human
Target Interferon α/β receptor
Clinical data
Routes of
administration
Intravenous
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C6444H9964N1712O2018S44
Molar mass 145.12 kg/mol

Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.[2]

This drug was developed by MedImmune, which chose to move anifrolumab instead of sifalimumab into Phase III trials for lupus in 2015.[3][4][5]

Adverse effects[edit]

The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[6]

References[edit]

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
  3. ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017. 
  4. ^ "Anifrolumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017. 
  5. ^ "Anifrolumab". AdisInsight. Retrieved 31 July 2017. 
  6. ^ H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).